How RITUXAN is Thought to Work
RITUXAN can be an Important Part of Treatment for Many of Your Chronic Lymphocytic Leukemia (CLL) Patients
RITUXAN is not chemotherapy. RITUXAN is a type of antibody therapy that targets and attaches to the CD20 protein found on the surface of CLL cells and some healthy blood cells. Once attached to the CD20 protein, RITUXAN works in 2 different ways:
- By helping your patient’s own immune system destroy the cancer cells
- By destroying the cancer cells on its own
In addition, RITUXAN can also harm healthy cells in the body.
You may prescribe chemotherapy along with RITUXAN.
This depends on the type of cancer and the treatment you prescribed. During the treatment program, patients may have a combination of side effects from both chemotherapy and RITUXAN. Follicular lymphoma patients whose initial treatment with RITUXAN + chemotherapy was successful and who use RITUXAN alone as maintenance therapy will not have side effects from chemotherapy because these patients will no longer be receiving chemotherapy. These patients, however, still may experience side effects from RITUXAN.
Have patients advise you on any side effects that bother them or that do not go away.
Please see Important Safety Information for RITUXAN below.